Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

novartis_hq_day

Novartis in $665 million deal for Selexys

November 21, 2016 Sales and Marketing Novartis, SelG1, selexys

Novartis have confirmed the acquisition of Selexys Pharmaceuticals, after Selexys received positive results from a Phase II trial. Novartis had …
News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

November 18, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Crohn's, Janssen, otezla, top ten

While the world is still reeling from the US presidential election results; it’s business as usual for the pharma industry; …
News
valeant

Former Valeant executive and Philidor CEO charged with fraud

November 18, 2016 Medical Communications, Sales and Marketing Philidor, Valeant, Valeant Pharmaceuticals, fraud

Gary Tanner, former executive, and Andrew Davenport, ex-CEO of Philidor, have been arrested and charged with fraud. Preet Bharara, US …
News
humacao_exterior

NICE thumbs up for BMS leukaemia treatment

November 18, 2016 Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia

Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
News
twitter_phone

New healthcare app aims to improve patient adherence

November 17, 2016 Medical Communications, Sales and Marketing Echo, app, patient adherence, smartphone

The newly released app, named Echo, was developed by former Apple executive Dr Sai Lakshmi and former LloydsPharmacy executive Stephen …
News
flag_of_japan_

Japan to slash Opdivo costs by 50%

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Japan, opdivo

Japan’s health ministry has announced it is to slash the price of Bristol-Myers Squibb’s Opdivo by 50% in the country …
News
amgen_hq

Amgen boosted in race to market for migraine drug

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …
News
nice_reception

NICE rules Shire’s Onivyde not cost effective

November 17, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, NICE, Onivyde, Shire

Shire’s Onivyde has been determined by NICE as not cost effective, in draft guidance, despite adding on average two months …
News
images

NICE approves Roche’s Perjeta for breast cancer

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer

NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
News

Myelofibrosis market to increase to be worth over $1 billion by 2025

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, US, myelofibrosis

The myelofibrosis market is expected to grow from $545.2 million in 2015 to $1.02 billion by 2025, almost doubling in …
News
shutterstock_292920209

Real world evidence: a reality check for pharma?

November 16, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing real world evidence

Rising demands on the industry has pharma firms calling for a more-effective, fit-for-purpose methodology for generating clinical data. Could the …
Feature

Abbott-St. Jude $25 billion deal close to clearance

November 16, 2016 Research and Development, Sales and Marketing Abbott, St. Jude, acquisition

EU antitrust regulators are due to reach a decision on the deal on 23 November that would see Abbott Laboratories …
News
janssen_latest_logo_on_sign_closer

Janssen’s Crohn’s treatment licensed for UK use

November 16, 2016 Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara

Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …
News
celgene_1_02

NICE rejects Celegene’s Revlimid as second-line treatment

November 16, 2016 Research and Development, Sales and Marketing Celegene, Revlimid

NICE has decided Celegene’s multiple myeloma growth engine Revlimid (lenalidomide) will not be offered to patients as a second line …
News
nordic-nanovector-big

New CMO and Executive Management Team member for Nordic Nanovector

November 15, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Nordic Nanovector has recruited a new chief medical officer (CMO) and Executive Management Team member with the appointment of Dr …
Appointment
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026